Analyzing TP53 Mutations in Breast Cancer Using Fine-Needle Aspirates
Author Information
Author(s): C Lavarinol, V Corletto, A Mezzelani, G Della Torre, C Bartoli, C Rival, MA Pierotti, F Rilke, S Pilottil
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Can fine-needle aspiration (FNA) material be used to analyze TP53 mutations and other biological parameters in breast carcinoma?
Conclusion
The study demonstrates that FNA can effectively assist in clinical decisions by evaluating various biological parameters relevant for prognosis and treatment planning.
Supporting Evidence
- Six cases showed positive nuclear staining for p53 protein.
- Nine mutations were detected in the TP53 gene.
- Twenty-six out of twenty-nine cases were aneuploid.
- High MIB 1 immunostaining was found in 89% of cases.
- All TP53-mutated cases were aneuploid.
- Immunoreactivity correlated with the type of gene mutation.
Takeaway
Doctors can use a special needle to take samples from breast tumors to check for important changes in genes that help decide how to treat the cancer.
Methodology
The study used immunocytochemistry, PCR-SSCP, DNA sequencing, and FISH analysis on FNA samples from patients with breast carcinoma.
Potential Biases
Potential bias due to the selection of patients and the reliance on FNA samples, which may not represent the entire tumor.
Limitations
The study did not evaluate mutations outside exons 5-8, which may affect the results.
Participant Demographics
All participants were female patients aged 25-71 years, with a mean age of 53.
Statistical Information
P-Value
0.0007
Statistical Significance
p=0.0007
Want to read the original?
Access the complete publication on the publisher's website